Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 480 IDR -1.33%
Market Cap: 68.4T IDR
Have any thoughts about
Kalbe Farma Tbk PT?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Kalbe Farma Tbk PT

Revenue
31.6T IDR
Cost of Revenue
-19.8T IDR
Gross Profit
11.8T IDR
Operating Expenses
-7.8T IDR
Operating Income
3.9T IDR
Other Expenses
-902.6B IDR
Net Income
3T IDR

Margins Comparison
Kalbe Farma Tbk PT Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
ID
Kalbe Farma Tbk PT
IDX:KLBF
68.9T IDR
37%
12%
10%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
749.7B USD
81%
35%
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
85%
44%
35%
US
Johnson & Johnson
NYSE:JNJ
372B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
257.3B USD
77%
34%
19%
CH
Roche Holding AG
SIX:ROG
200.4B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
179.9B CHF
75%
31%
35%
IE
Endo International PLC
LSE:0Y5F
146B USD
68%
11%
-126%
Country ID
Market Cap 68.9T IDR
Gross Margin
37%
Operating Margin
12%
Net Margin
10%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.4T DKK
Gross Margin
85%
Operating Margin
44%
Net Margin
35%
Country US
Market Cap 372B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Operating Margin
34%
Net Margin
19%
Country CH
Market Cap 200.4B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 162.7B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 179.9B CHF
Gross Margin
75%
Operating Margin
31%
Net Margin
35%
Country IE
Market Cap 146B USD
Gross Margin
68%
Operating Margin
11%
Net Margin
-126%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Kalbe Farma Tbk PT Competitors

Country Company Market Cap ROE ROA ROCE ROIC
ID
Kalbe Farma Tbk PT
IDX:KLBF
68.9T IDR
15%
11%
17%
13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
749.7B USD
66%
13%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
89%
27%
75%
35%
US
Johnson & Johnson
NYSE:JNJ
372B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
257.3B USD
28%
11%
25%
20%
CH
Roche Holding AG
SIX:ROG
200.4B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
162.7B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
179.9B CHF
45%
17%
24%
16%
IE
Endo International PLC
LSE:0Y5F
146B USD
70%
-51%
5%
6%
Country ID
Market Cap 68.9T IDR
ROE
15%
ROA
11%
ROCE
17%
ROIC
13%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 749.7B USD
ROE
66%
ROA
13%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.4T DKK
ROE
89%
ROA
27%
ROCE
75%
ROIC
35%
Country US
Market Cap 372B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 257.3B USD
ROE
28%
ROA
11%
ROCE
25%
ROIC
20%
Country CH
Market Cap 200.4B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 162.7B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 179.9B CHF
ROE
45%
ROA
17%
ROCE
24%
ROIC
16%
Country IE
Market Cap 146B USD
ROE
70%
ROA
-51%
ROCE
5%
ROIC
6%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top